HiSiaddi is an innovative foreign trade service provider driven by technology transformation and cross-border trading. We have established a "1+2+3+4=1" service system and can supply L-theanine sourced from multiple well-known original manufacturers.
As a technology-driven foreign trade enterprise, HiSiaddi has repeatedly collaborated with factories on technology conversion and accurately captured market demands to propose L-theanine product formula optimization schemes and application improvement suggestions. Below is a case of L-theanine formula optimization consulting service delivered by HiSiaddi.
Contact HiSiaddi customer service for more formula optimization consulting services.
The purchaser is NUTRABIO Inc., headquartered in Los Angeles, California, a leading mid-to-high-end dietary nutrition brand in North America specializing in hospital-grade calming tablets and effervescent solid beverages distributed across national chain pharmacies and private health institutions. Raw materials comply with US USP, cGMP and California food raw material control standards, with long-term fixed procurement of imported high-purity L-theanine.
Faced with rising overseas raw material prices, the client purchased 22 tons of national standard premium L-theanine from domestic suppliers. Upon delivery and production launch, systematic technical failures occurred on two core production lines, halting mass production of new products and risking scrappage of semi-finished inventory. The client’s original mature formula was: 32% L-theanine + microcrystalline cellulose + lactose + plant flow aid, deployed across tablet formulation and solid powder product lines. Four typical technical failures emerged post-production launch:
1. Poor powder flowability for tableting: Material bridging and hopper blockages, excessive tablet weight fluctuation. Raw materials contained excessive acicular crystals and fine powder with angle of repose >46°, causing inconsistent feeding volume, out-of-spec RSD of tablet weight failing FDA incoming factory inspection, and frequent shutdowns of high-speed tablet presses for hopper cleaning.
2. White bloom precipitation on tablet surface and severe punch sticking: White crystals adhered to tablet press dies, and white bloom appeared on tablet surfaces after 15 days of ambient storage, failing shelf stability requirements for supermarket shelf life.
3. Hygroscopic caking of solid beverage powder and turbid precipitation upon reconstitution: Excessive raw material moisture and trace residual solvents caused caking after ambient storage of compounded powder, with insoluble flocs forming during warm water reconstitution, failing sensory and physicochemical standards.
4. Rapid efficacy attenuation under accelerated stability testing: After 30 days of constant temperature accelerated testing at 40℃, calming active efficacy declined by over 22%, with abnormal elevation of pyroglutamic acid impurities leading to premature failure of the formula system.
The client contacted domestic suppliers for technical rectification, yet manufacturers could only provide factory release COAs without downstream formulation R&D capabilities. They merely suggested adjusting feeding ratios and failed to trace rectification from raw material crystal form, impurities and compatibility logic. Multiple small trials of formula fine-tuning yielded no improvements. The client entrusted HiSiaddi, equipped with amino acid process and formulation engineer teams, to conduct full-chain root cause investigation and optimize raw materials, end-product formulas and production processes.
HiSiaddi collected samples of the client’s in-use raw materials and semi-finished products, and collaborated with CNAS third-party labs for full testing, comparing data against the client’s original imported L-theanine quality control benchmarks to identify dual inducements of inherent raw material defects and mismatched formula design.
① Disordered crystal forms: Crude single recrystallization produces mixed acicular and fine powder materials with particle sizes ranging from 20 to 200 mesh and fine powder proportion exceeding 35% – the core cause of poor flowability, bridging and punch sticking. ② Excessive moisture and residual solvents: Raw material moisture reached 0.38% (client internal control ≤0.18%), with ethanol and isopropanol residuals of 38ppm. Small molecule migration during high-temperature storage triggered surface bloom and powder hygroscopic caking. ③ Elevated trace impurities: Combined D-type chiral isomers and pyroglutamic acid byproducts reached 0.72%, which sustained oxidative degradation during high-temperature storage, disrupting the compatibility system and causing efficacy attenuation and turbid solutions. ④ Trace heavy metal excess: Minor lead and inorganic impurities damaged the compatibility stability of lactose and cellulose excipients, accelerating hydrolytic deterioration of auxiliary materials.
The original formula was designed for imported spherical granular high-purity L-theanine and failed to adapt to the physical properties of domestic acicular raw materials. Flow aid and binder addition ratios retained parameters for imported materials without targeted fine-tuning of auxiliary materials, and the powder formula lacked a customized moisture-proof system matching domestic raw materials’ hygroscopicity.
1. Crystallization process adjustment: Adopted segmented gradient temperature-controlled recrystallization with optimized cooling rates to transform acicular crystals into regular short columnar particles. Particle size was strictly controlled at 70–120 mesh, fine powder proportion reduced to below 8%, and angle of repose lowered to within 36°, fundamentally improving powder flowability.
2. Refining & impurity removal: Added ion exchange resin sections to strip heavy metals and byproducts, paired with secondary low-temperature vacuum drying to reduce moisture to 0.15% and total residual solvents ≤20%. Combined D-type isomer and pyroglutamic acid impurities were controlled ≤0.19% to eliminate post-storage precipitation and oxidative deterioration.
3. Aseptic sieving: Closed crushing and classification in Class D clean workshops to reduce additional fine powder generated during production. USP-aligned test COAs were issued for improved raw materials, with 5kg optimized samples airfreighted to the US for small trials.
1. Formula fine-tuning: L-theanine feeding proportion reduced from 32% to 29.5%, with adjusted ratios of microcrystalline cellulose and direct-compression lactose. A composite flow and anti-sticking system of 0.4% silicon dioxide + 0.6% magnesium stearate was added to improve powder flowability and anti-hygroscopic performance.
2. Process optimization: Workshop humidity controlled at 45%–52% during tableting, moderate reduction of tablet press speed, and cooling water circulation for pressing dies. Low-temperature side feeding of raw materials was adopted to avoid punch sticking caused by high machine temperature melting.
1. Added 1.2% modified maltodextrin moisture-proof carrier, adopting dry pre-mixing granulation to encapsulate fine L-theanine powder and isolate air and moisture, resolving hygroscopic caking and dissolution precipitation issues.
1. Qualified mass pilot verification: The client conducted small-batch mass production of 500kg using improved raw materials and optimized formulas. Smooth feeding without bridging was observed for tablets, tablet weight variation complied with US Pharmacopoeia standards, and no white bloom precipitation occurred after 90 days of ambient storage. Solid powder showed no caking during storage with clear reconstitution free of sediment, and efficacy attenuation under accelerated stability testing was controlled within 4%, enabling full production line resumption.
2. Revitalization of existing 22 tons of old inventory to reduce client losses: HiSiaddi provided a compromise utilization plan for undelivered unimproved raw materials – mixing old and improved materials at a 3:7 ratio for feeding, paired with optimized formulas and production parameters to fully consume all inventory evenly over 4 months, avoiding high ocean freight and port detention losses from full batch return shipments.
3. Signing of annual long-term agreement: After 3 months of stable mass production, comprehensive procurement costs of domestic improved L-theanine decreased by 28.6% compared with imported raw materials. The client signed an annual procurement order of 190 tons, agreeing to standardized mass production of raw materials with customized crystal form and impurity indicators. Subsequent R&D of new plant-compounded L-theanine raw materials and pre-formula testing were fully assigned to HiSiaddi’s technical team.
4. Long-term technical support: HiSiaddi established batch product archives, supplying USP test reports with each factory release, and tracking updates to US raw material regulations to predict indicator adjustments in advance. Free gradient samples and formula references are provided for new product R&D phases.
1. Physical property gap between domestic food-grade L-theanine and high-end North American formulation raw materials: Domestic manufacturers set national standard content as the production baseline without controlling crystal form, particle size and trace impurities for downstream tableting and powder applications. Standard spot goods only fit low-end bulk raw material demand and cannot directly meet formulation requirements of US hospital-grade health products. Most factories lack downstream formulation R&D capabilities and can only control factory release indicators without resolving terminal production failures.
2. Distinct procurement logic for mid-to-high-end overseas buyers compared with low-volume retail purchasers: US hospital-grade health product buyers prioritize raw material physical compatibility, formula compatibility and shelf stability over unit price as hard market access thresholds. Minor raw material impurities or crystal form discrepancies can trigger full production line shutdown and product scrappage.
3. HiSiaddi’s core advantage: Dual technical empowerment covering raw material production processes and end-product formulation design, breaking the traditional foreign trade pure spot resale model. We coordinate with manufacturers to upgrade upstream production processes and assist clients in optimizing downstream end formulas and production processes, bridging the technical gap between raw material manufacturing and terminal formulation. Long-term repeat orders are secured through full-chain technical services.
Contact HiSiaddi customer service for more formula optimization consulting services.
+86-13120989737 
info@hisiaddi.com 
English
